Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial - The Lancet Gastroenterology & Hepatology
PLOS ONE: A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
Genentech: Statements | Genentech Statement on Counterfeit Drug Labeled as Avastin® (Bevacizumab) in the United States
Avastin - FDA prescribing information, side effects and uses
avastin - Diabetic Retinopathy
ICD-9/10 codes to define serious adverse events for Bevacizumab based... | Download Scientific Diagram
Avastin approval for breast cancer pulled | CBC News
Italy free to reimburse off-label Avastin, rules EU court -
Avastin disappoints against ovarian cancer | KCBY
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label,
![PDF] Off-label use of bevacizumab for wet age-related macular degeneration in Europe | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/dd8a688b93d7c74f55bbed645b027d6775de792f/6-Table1-1.png "PDF] Off-label use of bevacizumab for wet age-related macular degeneration in Europe | Semantic Scholar")
PDF] Off-label use of bevacizumab for wet age-related macular degeneration in Europe | Semantic Scholar
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer - Journal of Thoracic Oncology
PDF) Bevacizumab: Off-label use in ophthalmology
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
Roche - Avastin (bevacizumab)
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial - The Lancet Oncology
Immunotherapy Regimen Approved for Hepatocellular Carcinoma - MPR
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open- label, phase 3 trial - The Lancet
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study - The Lancet Oncology
NHS wins legal fight against pharma firms over sight-loss drug | NHS | The Guardian
Genentech warns of fake Avastin
Five cancer drugs back on NHS list after deals with drug companies | The BMJ
File:Bevacizumab label 01.jpg - wikidoc
